Amphastar Pharmaceuticals Share Price (NASDAQ: AMPH)

$30.52

▲

0.86

(2.9%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Amphastar Pharmaceuticals Stock chart to analyse performance

Amphastar Pharmaceuticals stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$30.17
Today's High:$30.85
$30.52
1.15%
Downside
Day's Volatility :2.2%
Upside
1.07%
52 Weeks Low:$20.39
52 Weeks High:$53.96
$30.52
33.21%
Downside
52 Weeks Volatility :62.22%
Upside
43.43%

Amphastar Pharmaceuticals Stock Returns

Period	Amphastar Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	19.47%	6.0%	0.0%
6 Months	-5.54%	-5.6%	0.0%
1 Year	-36.39%	-11.1%	0.0%
3 Years	-4.03%	6.8%	-7.8%

Amphastar Pharmaceuticals Inc Key Stats

Check Amphastar Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$29.66
Open	$30.2
Today's High	$30.85
Today's Low	$30.17
Market Capitalization	$1.4B
Today's Volume	$494.9K
52 Week High	$53.955
52 Week Low	$20.385
Revenue TTM	$722.7M
EBITDA	$236.7M
Earnings Per Share (EPS)	$2.67
PE Ratio	11.11
Profit Margin	18.64%
Quarterly Earnings Growth YOY	-0.12%
Return On Equity TTM	18.32%

Stock Returns calculator for Amphastar Pharmaceuticals Stock including INR - Dollar returns

The Amphastar Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Amphastar Pharmaceuticals investment value today

Current value as on today

₹67,965

Returns

₹32,035

(-32.03%)

Returns from Amphastar Pharmaceuticals Stock

₹36,350 (-36.35%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Amphastar Pharmaceuticals Stock

364%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Amphastar Pharmaceuticals Stock from India on INDmoney has increased by 364% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Amphastar Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
13.22%
Vanguard Group Inc
5.78%
TD Asset Management Inc
4.38%
Dimensional Fund Advisors, Inc.
3.50%
State Street Corp
3.45%
Fuller & Thaler Asset Management Inc
2.72%

Analyst Recommendation on Amphastar Pharmaceuticals Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Amphastar Pharmaceuticals(by analysts ranked 0 to 5 stars)

Amphastar Pharmaceuticals Share Price Target

What analysts predicted

Upside of 4.85%

Target:

$32.00

Current:

$30.52

Amphastar Pharmaceuticals share price target is $32.00, a slight Upside of 4.85% compared to current price of $30.52 as per analysts' prediction.

Amphastar Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, AMPH stock has moved up by 34.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 170.52M → 174.41M (in $), with an average increase of 2.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 25.28M → 31.03M (in $), with an average increase of 18.5% per quarter
AMPH vs HLN (1 yr)
In the last 1 year, Amphastar Pharmaceuticals Inc has experienced a drawdown of -36.4%, however Haleon Plc Spon Ads resisted the overall trend and outperformed by 35.5%
AMPH vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 53.8% return, outperforming this stock by 59.7%
Price to Sales
ForAMPH every $1 of sales, investors are willing to pay $2.0, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

Amphastar Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$322.4M	↑ 9.4%
Net Income	$48.9M	↓ 952.89%
Net Profit Margin	15.18%	↑ 17.13%

	FY20	Y/Y Change
Revenue	$349.8M	↑ 8.53%
Net Income	$1.4M	↓ 97.13%
Net Profit Margin	0.4%	↓ 14.78%

	FY21	Y/Y Change
Revenue	$437.8M	↑ 25.13%
Net Income	$62.1M	↑ 4327.37%
Net Profit Margin	14.19%	↑ 13.79%

	FY22	Y/Y Change
Revenue	$499.0M	↑ 13.98%
Net Income	$91.4M	↑ 47.12%
Net Profit Margin	18.31%	↑ 4.12%

	FY23	Y/Y Change
Revenue	$644.4M	↑ 29.14%
Net Income	$137.5M	↑ 50.51%
Net Profit Margin	21.34%	↑ 3.03%

	FY24	Y/Y Change
Revenue	$712.8M	↑ 10.62%
Net Income	$159.5M	↑ 15.98%
Net Profit Margin	22.38%	↑ 1.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$171.8M	↓ 3.52%
Net Income	$43.2M	↑ 19.38%
Net Profit Margin	25.13%	↑ 4.82%

	Q2 FY24	Q/Q Change
Revenue	$182.4M	↑ 6.14%
Net Income	$37.9M	↓ 12.11%
Net Profit Margin	20.81%	↓ 4.32%

	Q3 FY24	Q/Q Change
Revenue	$188.8M	↑ 3.52%
Net Income	$40.4M	↑ 6.54%
Net Profit Margin	21.41%	↑ 0.6%

	Q4 FY24	Q/Q Change
Revenue	$186.5M	↓ 1.22%
Net Income	$38.0M	↓ 6.1%
Net Profit Margin	20.35%	↓ 1.06%

	Q1 FY25	Q/Q Change
Revenue	$170.5M	↓ 8.58%
Net Income	$25.3M	↓ 33.4%
Net Profit Margin	14.83%	↓ 5.52%

	Q2 FY25	Q/Q Change
Revenue	$174.4M	↑ 2.28%
Net Income	$31.0M	↑ 22.72%
Net Profit Margin	17.79%	↑ 2.96%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$131.9M	↑ 23.31%

	FY20	Y/Y Change
Profit	$143.3M	↑ 8.65%

	FY21	Y/Y Change
Profit	$199.7M	↑ 39.35%

	FY22	Y/Y Change
Profit	$248.9M	↑ 24.59%

	FY23	Y/Y Change
Profit	$351.1M	↑ 41.09%

	FY24	Y/Y Change
Profit	$373.9M	↑ 6.47%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$87.3M	↓ 6.71%

	Q2 FY24	Q/Q Change
Profit	$92.0M	↑ 5.45%

	Q3 FY24	Q/Q Change
Profit	$101.9M	↑ 10.75%

	Q4 FY24	Q/Q Change
Profit	$86.6M	↓ 15.0%

	Q1 FY25	Q/Q Change
Profit	$85.3M	↓ 1.61%

	Q2 FY25	Q/Q Change
Profit	$86.5M	↑ 1.45%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$41.8M	↑ 9.35%
Investing Cash Flow	$-50.5M	↑ 19.78%
Financing Cash Flow	$-3.8M	↓ 115.13%

	FY20	Y/Y Change
Operating Cash Flow	$57.3M	↑ 37.12%
Investing Cash Flow	$-36.4M	↓ 27.93%
Financing Cash Flow	$-2.2M	↓ 40.63%

	FY21	Y/Y Change
Operating Cash Flow	$98.0M	↑ 71.12%
Investing Cash Flow	$-28.7M	↓ 21.26%
Financing Cash Flow	$-37.0M	↑ 1548.17%

	FY22	Y/Y Change
Operating Cash Flow	$89.2M	↓ 8.99%
Investing Cash Flow	$-32.8M	↑ 14.32%
Financing Cash Flow	$-26.4M	↓ 28.58%

	FY23	Y/Y Change
Operating Cash Flow	$183.5M	↑ 105.76%
Investing Cash Flow	$-649.1M	↑ 1880.4%
Financing Cash Flow	$454.1M	↓ 1817.51%

	FY24	Y/Y Change
Operating Cash Flow	$213.4M	↑ 16.28%
Investing Cash Flow	$-124.9M	↓ 80.75%
Financing Cash Flow	$-81.0M	↓ 117.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$55.3M	↑ 131.69%
Investing Cash Flow	$15.2M	↓ 114.79%
Financing Cash Flow	$-13.6M	↓ 71.16%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$69.1M	↑ 24.99%
Investing Cash Flow	$-69.9M	↓ 558.77%
Financing Cash Flow	$-10.7M	↓ 21.08%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$60.0M	↓ 13.24%
Investing Cash Flow	$-34.6M	↓ 50.52%
Financing Cash Flow	$-22.8M	↑ 112.92%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$29.0M	↓ 51.6%
Investing Cash Flow	$-35.7M	↑ 3.16%
Financing Cash Flow	$-33.8M	↑ 48.33%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$35.1M	↑ 20.86%
Investing Cash Flow	$10.5M	↓ 129.38%
Financing Cash Flow	$-14.5M	↓ 57.14%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$35.6M	↑ 1.47%
Investing Cash Flow	$-625.0K	↓ 105.96%
Financing Cash Flow	$-30.2M	↑ 108.25%

Amphastar Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Amphastar Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Amphastar Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amphastar Pharmaceuticals Inc	35.5%	-5.54%	-36.39%	-4.03%	51.59%
Haleon Plc Spon Ads	-0.41%	-3.35%	-0.91%	55.47%	32.39%
United Therapeutics Corporation	1.94%	-12.81%	-10.25%	40.38%	75.65%
Zoetis Inc.	2.46%	-5.28%	-13.44%	-3.72%	-0.11%
Neurocrine Biosciences Inc.	2.8%	13.62%	-11.44%	26.96%	21.38%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amphastar Pharmaceuticals Inc	11.11	11.11	2.77	3.3	0.18	0.07	NA	16.29
Haleon Plc Spon Ads	21.8	21.8	3.15	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.18	12.18	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.74	26.74	2.54	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	40.02	40.02	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amphastar Pharmaceuticals Inc	Buy	$1.4B	51.59%	11.11	18.64%
Haleon Plc Spon Ads	Buy	$44.6B	32.39%	21.8	13.81%
United Therapeutics Corporation	Buy	$14.1B	75.65%	12.18	40.36%
Zoetis Inc.	Buy	$69.0B	-0.11%	26.74	27.83%
Neurocrine Biosciences Inc.	Buy	$13.4B	21.38%	40.02	13.88%

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Organization	Amphastar Pharmaceuticals
Employees	2028
CEO	Dr. Yongfeng Zhang Ph.D.
Industry	Health Technology

Key Management of Amphastar Pharmaceuticals Inc

Name	Title
Dr. Ziping Luo Ph.D.	Chairman of the Board, Chief Scientist & COO
Dr. Yongfeng Zhang Ph.D.	Co-Founder, President, CEO, Chief Scientific Officer & Director
Mr. William J. Peters M.B.A.	CFO, Executive VP of Finance, Treasurer & Director
Mr. Jacob Liawatidewi M.B.A.	Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Mr. Rong Zhou M.S.	Senior EVP of Production & EVP of Scientific Affairs
Mr. Dan Dischner M.B.A.	Senior Vice President of Human Resources & Corporate Communication
Tony Marrs M.B.A., M.P.H., M.S.	Executive VP of Regulatory Affairs & Clinical Operations

Important FAQs about investing in AMPH Stock from India :

What is Amphastar Pharmaceuticals share price today?

Amphastar Pharmaceuticals share price today is $30.52 as on August 23, 2025 at 1:29 AM IST at the close of the market. Amphastar Pharmaceuticals share today touched a day high of $30.85 and a low of $30.17.

What is the 52 week high and 52 week low for Amphastar Pharmaceuticals share?

Amphastar Pharmaceuticals share touched a 52 week high of $53.96 and a 52 week low of $20.39. Amphastar Pharmaceuticals stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $30.52, lower by 43.43% versus the 52 week high.

How to invest in Amphastar Pharmaceuticals Stock (AMPH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Amphastar Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amphastar Pharmaceuticals Shares that will get you 0.0491 shares as per Amphastar Pharmaceuticals share price of $30.52 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Amphastar Pharmaceuticals Stock (AMPH) from India?

Indian investors can start investing in Amphastar Pharmaceuticals (AMPH) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Amphastar Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Amphastar Pharmaceuticals share’s latest price of $30.52 as on August 23, 2025 at 1:29 AM IST, you will get 0.3277 shares of Amphastar Pharmaceuticals. Learn more about fractional shares .

What are the returns that Amphastar Pharmaceuticals has given to Indian investors in the last 5 years?

Amphastar Pharmaceuticals stock has given 51.59% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?